Posted by Michael Wonder on 14 Jun 2023
Health economic assessment of Pluvicto in advanced prostate cancer
12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan).
The assessment applies to Pluvicto for the treatment of patients with advanced castration-resistant prostate cancer who have previously received anti-hormonal therapy and at least one line of chemotherapy.
